|
1. BIOLOGIE
|
|
|
|
|
Tumor Microbiome Appears to Vary With Cancer Type [Genome Web]
|
|
|
|
|
|
In an effort to take a closer look at these microbial communities, the team turned to 16S ribosomal gene sequencing and quantitative PCR to identify and quantify bacteria present in 1,010 tumor samples and more than 500 neighboring normal tissue samples.
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
A boost for cancer immunotherapy [MIT]
|
|
|
|
|
|
MIT engineers have now come up with a way to boost the effectiveness of one type of cancer immunotherapy. They showed that if they treated mice with existing drugs called checkpoint inhibitors, along with new nanoparticles that further stimulate the immune system, the therapy became more powerful than checkpoint inhibitors given alone.
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
|
|
|
|
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020 [EMA]
|
|
|
|
|
|
Piqray (alpelisib) received a positive opinion from the CHMP for the treatment of locally advanced or metastatic breast cancer with a PIK3CA mutation. The CHMP recommended granting a conditional marketing authorisation for Rozlytrek (entrectinib), for the treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion, or patients with ROS1-positive advanced non-small cell lung cancer.
|
|
|
|
|
|
|
5.5.3 ASCO (PROSTATE)
|
|
|
|
5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
|
|
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|